Iron deficiency is a multisystem disorder that affects patients with chronic kidney disease (CKD), cardiovascular diseases, cancer, inflammatory conditions, bariatric surgery, menorrhagia, and postpartum bleeding.^[1] Beyond its critical role in erythropoiesis, iron is essential for mitochondrial energy production, enzymatic functions, immune regulation, and neurological health. In CKD, iron deficiency can be classified as absolute iron deficiency, characterized by depleted iron stores due to blood loss, impaired gastrointestinal absorption, and inadequate replenishment, or functional iron deficiency, where iron stores are adequate but unavailable for effective red blood cell production. Factors such as chronic inflammation, elevated hepcidin levels, ESA therapy, and ongoing blood losses contribute significantly to iron deficiency in these patients.While oral iron supplements remain a treatment option, limitations in absorption, tolerability, and adherence often necessitate intravenous (IV) iron therapy. Advances in IV iron formulations, particularly Ferric carboxymaltose (FCM), a contemporary parenteral iron formulation that used therapeutically to treat anemia caused by an iron deficiency.^[2] Compared with earlier IV iron products, FCM allows higher-dose administration with reduced risk of immunogenic reactions and improved patient convenience. Adherence to established reference product standards is critical in FCM manufacturing, as carbohydrate content directly influences formulation stability, iron delivery, shelf life, and clinical performance. Consistent quality ensures optimal therapeutic outcomes and safe correction of iron deficiency anemia.